AMA Knows a Thing or Two About Social Media: Day 2 @ PhRMA Social Media Summit

AMA Knows a Thing or Two About Social Media: Day 2 @ PhRMA Social Media Summit

07.27.12 | By Christian Clymer

Yesterday we wrapped up a successful PhRMA Social Media Summit at Astellas' Americas HQ, focusing on best practices and information sharing with a presentation from the American Medical Association (AMA).

Kevin O'Neil, AMA's director of physician communications, and Nick Abruzzo, AMA's vice president of interactive marketing, showcased the organization's blog ("On the Road with Dr. Lazarus") as one of many successful examples of how AMA is communicating with members and core stakeholders. Both Kevin and Nick admitted that physicians are not easy to reach across social channels, but that AMA prioritizes innovative and compelling content amplified by attention-grabbing headlines, testing subject lines to determine what generates the most interest and focusing on including an educational or data component. Additionally, as the speakers noted, success in social media is really about trial and error.

Next up on AMA's list for enhancing its community building efforts: popular content sharing site Pinterest.

Following the morning presentation, we split participants into two separate groups to compile best practices and near-term ideas for doing more to contribute to conversations about innovation. At the summit, we were fortunate to have a number of external stakeholders join us, all of whom will have an important role to play in elevating the health care discourse.

The two-day event was a tremendous success and we look forward to continuing the dialogue and sharing what we learned in the days and weeks ahead. There is clearly a lot to learn as patients, providers and stakeholders work together.

Stay tuned here for additional innovation content or let us know what you think via the comments section, Facebook and Twitter @PhRMA. And for more from Kevin and Nick, follow them on Twitter @kjo84 and @nickabruzzo.

More On PhRMA — powered by PhRMApedia


Cost in Context